Retirement Planning Group LLC Trims Stake in Eli Lilly and Company $LLY

Retirement Planning Group LLC trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 20.6% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 369 shares of the company’s stock after selling 96 shares during the period. Retirement Planning Group LLC’s holdings in Eli Lilly and Company were worth $287,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. WestEnd Advisors LLC grew its position in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after buying an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company during the first quarter worth about $27,000. Citizens National Bank Trust Department grew its position in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after buying an additional 27 shares in the last quarter. Blume Capital Management Inc. grew its position in Eli Lilly and Company by 46.7% during the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after buying an additional 14 shares in the last quarter. Finally, IMG Wealth Management Inc. purchased a new position in Eli Lilly and Company during the second quarter worth about $35,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research reports. Cantor Fitzgerald set a $925.00 price objective on Eli Lilly and Company and gave the stock an “overweight” rating in a report on Thursday, October 9th. JPMorgan Chase & Co. cut their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, September 16th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Leerink Partners reiterated a “market perform” rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 7th. Finally, Morgan Stanley cut their price objective on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a report on Friday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $938.61.

Eli Lilly and Company Trading Up 1.6%

NYSE LLY opened at $812.33 on Thursday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $935.63. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a 50-day moving average of $762.81 and a 200-day moving average of $766.75. The firm has a market cap of $768.84 billion, a PE ratio of 53.09, a price-to-earnings-growth ratio of 1.14 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the previous year, the company posted $3.92 EPS. Eli Lilly and Company’s revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Buying and Selling

In other Eli Lilly and Company news, Director Gabrielle Sulzberger purchased 117 shares of the stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director directly owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director J Erik Fyrwald purchased 1,565 shares of the stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,514 shares of company stock worth $2,894,841 in the last 90 days. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.